Stereoselective rearrangement of 5,6-epoxy carotenoid model compounds

Yumiko Yamano, Chisato Tode and Masayoshi Ito*

Kobe Pharmaceutical University, Motoyamakita-machi, Higashinada-ku, Kobe 658, Japan

Carotenoids with novel acyclic tetrasubstituted olefinic and cyclopentyl end groups are obtained by Lewis acidpromoted stereoselective rearrangement of the epoxide end group of 5,6-epoxy carotenoids.

Marine carotenoids halocynthiaxanthin $1, {}^{1}$ mytiloxanthin 2^{2} and crassostreaxanthin B $3^{1b,3}$ (Scheme 1) have characteristic structures, commonly possessing a monoacetylenic end group. The cyclopentyl end group of mytiloxanthin 2 is believed ⁴ to be formed in nature from the epoxide end group of 5,6-epoxy carotenoids \dagger such as halocynthiaxanthin 1 by cleavage of the oxirane ring at the C-5 position and successive ring contraction (a pinacolic rearrangement) (Scheme 1, route *a*). It is also conceivable that crassostreaxanthin B 3, including the novel tetrasubstituted olefinic end group, arises from epoxy carotenoids by opening of the C-6–oxygen bond of the oxirane ring and subsequent migration of the methyl group at the C-1 position (route *b*). In order to confirm chemically the hypothetical biosynthetic mechanism of these carotenoids, we examined the reaction of epoxides 5 and 7 (Scheme 2) having a part structure of epoxy carotenoids with Lewis acids.

Rüttimann reported ⁵ that treatment of epoxides **4** and **6** with $BF_3 \cdot OEt_2$ followed by hydrolysis yielded cyclopentyl methyl ketones **8** and **13**, respectively, each as a single product in up to 70% yield. Then he proposed the possible intermediates I and II deriving from 'axial' cleavage of the respective epoxides. However, the mechanism for the formation of the methyl ketone **8** from the *anti*-epoxide **4** is in conflict with the proposed biosynthetic mechanism ⁴ of mytiloxanthin **2**. Since substituents

† We have employed the numbering system used in carotenoids.



at the C-5 and C-6 positions of these epoxides are both methyl groups, the direction of the oxirane ring opening can not be proved. Thus, epoxides 5 and 7 having an ethyl group at C-6 were treated with BF_3 ·OEt₂.



Scheme 1

Epoxides 5 and 7 were prepared in 9 steps from the known⁶ optically active ketone 17 in good overall yield as shown in Scheme 3. The key step was the effective conversion of the



Scheme 3 Reagents and conditions: i, LiC=CTMS; ii, 10% aq. KOH; iii, Ac₂O, py; iv, TPSV, PhCO₂H, xylene, reflux; v, NaBH₄; vi, MsCl, py; vii, LiAlH₄, THF, reflux; viii, MCPBA

α-acetylenic alcohol **18** into the β ,γ-unsaturated aldehyde **19** using tris(triphenylsilyl)vanadate (TPSV) as the catalyst.⁷ Application of the modified conditions [TPSV (0.02 equiv.) and PhCO₂H (0.02 equiv.) in the absence of triphenylsilanol] to the alcohol **18** afforded the desired aldehyde **19** in high yield. Relative configurations between acetoxy and epoxy groups in epoxides **5** and **7** were confirmed by their ¹H NMR spectroscopic data.⁶

Reaction of the anti-epoxide 5 with BF₃·OEt₂ (3 equiv.; CH_2Cl_2 ; -78 °C for 3 h, then 0 °C for 1 h) gave the acyclic tetrasubstituted olefinic methyl ketone 12 (54%) having the partial structure of crassostreaxanthin B 3, and the cyclopentyl ethyl ketone 10 (31%) possessing the same configuration as mytiloxanthin 2 (Scheme 2). In this reaction, the cyclopentyl methyl ketone 16 arising through the intermediate I⁵ was not obtained. Thus, it was found that in the epoxide 5 cleavage of the oxirane ring at C-6 (route b) did not induce the skeletal transformation into the compound 16 but caused the migration of the methyl group at C-1 to give the compound 12. On the other hand, the five-membered ethyl ketone 10 was formed in the same pathway as the proposed biosynthetic mechanism⁴ of mytiloxanthin 2 (route a). Then, the same treatment of the synepoxide 7 provided the cyclopentyl ethyl ketone 15 (44%) and the compound 12 (49%). In addition, predominant formation of the novel olefinic methyl ketone 12 was found by treatment of the epoxide 5 with $SnCl_4$ (2 equiv.; -20 °C for 30 min, then 0 °C for 3 h) (10: trace; 12: 70%) and tris(4-bromophenyl)aminium hexachloroantimonate⁸ (0.1 equiv.; room temp. for 1.5 h) (10: 12%; 12: 71%).

Stereostructures of cyclopentyl ethyl ketones 10 and 15 were determined by the comparison of their ¹H NMR data with those of the known⁹ five-membered methyl ketones 9 and 14. The structure of the novel compound 12 was confirmed on the basis of its spectral data (see Experimental section), which failed to prove the geometry of the tetrasubstituted double bond. Thus, it was chemically determined by the synthesis of both isomers 12' and 29 as shown in Scheme 4.

Reaction of the ketone 22 with phosphorothioate 24 prepared according to the literature ¹⁰ and following reduction of the products gave alcohols 25 and 26, whose stereochemistries were determined by their NOESY measurements, shown in Scheme 4. Spectral properties of the *E*-olefinic methyl ketone 12' derived from the alcohol 26 were in good agreement with those of the compound 12 obtained from rearrangement of epoxides 5 and 7. In the NOESY spectra of the *Z*-isomer 29, cross-peaks between the methylene protons of the ethyl group and methylene protons at the C-5 position were observed. Hence, the stereoselective formation of the compound 12 from both *anti*- and *syn*-epoxides 5 and 7 could be accounted for through a concerted antiperiplanar pathway.

In addition, reaction of epoxides 4 and 6 with BF_3 -OEt₂ was reinvestigated. In the case of *syn*-epoxide 6, only the fivemembered methyl ketone 14 was obtained, whereas in the case of the *anti*-epoxide 4, the olefinic ketone 11 was found to be formed together with compound 9 (*ca.* 1:1).

This is the first report of novel acyclic tetrasubstituted olefinic compounds being produced by rearrangement of tetrasubstituted epoxides. These results support the proposed metabolism of 5,6-epoxy carotenoids.

Work is in progress on the biomimetic synthesis of 2 and 3 using the present results.

Experimental

Treatment of the anti-epoxide 5 with BF₃·OEt₂

To a stirred solution of the *anti*-epoxide 5 (300 mg, 1.3 mmol) in CH₂Cl₂ (10 cm³) was added dropwise 47% boron trifluoride diethyl ether complex (1.20 g, 4.0 mmol) at -78 °C under N₂. After being stirred at -78 °C for 3 h and at 0 °C for 1 h, the reaction mixture was diluted with CH₂Cl₂ and the organic layer was washed with saturated aqueous NaHCO₃ and brine. Evaporation of the dried (Na₂SO₄) solution gave a residue which was purified by column chromatography on silica gel (Et₂O-hexane, 3:7) to furnish the cyclopentyl ethyl ketone 10 (92 mg, 31%) and the tetrasubstituted olefinic methyl ketone 12 (163 mg, 54%).

Compound **10**: $[\alpha]_D^{21} - 6.54$ (*c* 0.92, MeOH); ν/cm^{-1} 1725 and 1700; $\delta_{\rm H}(500 \text{ MHz}; {\rm CDCl}_3; J/{\rm Hz})$ 0.83, 1.14 and 1.26 (each 3 H, s), 1.01 (3 H, t, *J* 7), 1.54 (1 H, dd, *J* 15, 3.5), 1.71 (1 H, dd, *J* 14.5, 4.5), 2.02 (3 H, s), 2.06 (1 H, dd, *J* 14.5, 8.5), 2.45 (2 H, qd-like, *J* 7, 1.5), 2.86 (1 H, dd, *J* 15, 8.5) and 5.22 (1 H, m) (Found: m/z 226.1568. $C_{13}H_{22}O_3$ requires *M*, 226.1570).

Compound 12: $[\alpha]_D^{25} - 1.69$ (*c* 1.18, MeOH); ν/cm^{-1} 1730; $\delta_H(500 \text{ MHz}; \text{CDCl}_3; J/\text{Hz}) 0.92$ (3 H, t, J 7.5), 1.67 (3 H, d-like, J 1), 1.69 (3 H, d-like, J 1), 1.98 (3 H, s), 2.10 (2 H, q, J 7.5), 2.16 (3 H, s), 2.19 (1 H, dd, J 13.5, 6), 2.42 (1 H, dd, J 13.5, 8), 2.60 (1 H, dd, J 16.5, 4.5), 2.70 (1 H, dd, J 16.5, 8) and 5.40 (1 H, tdd, J 8, 6, 4.5); $\delta_C(125 \text{ MHz}; \text{CDCl}_3)$, 12.3, 18.1, 18.3, 21.0, 27.6,



Scheme 4 Reagents and conditions: i, (EtO)₂P(O)SCH(Et)CO₂Me 24, LDA; ii, LiAlH₄; iii, MsCl, py; iv, LiAlH₄; v, p-TsOH; vi, LDA, acetone; vii, Ac₂O, py

30.3, 39.2, 47.8, 69.3, 122.7, 134.1, 170.1 and 205.7 (Found: *m*/*z* 226.1566. C₁₃H₂₂O₃ requires M, 226.1570).

Acknowledgements

We are indebted to Dr U. Hengartner, Hoffmann-La Roche Ltd., Basel, Switzerland for his gift of some (4R, 6R)-4-hydroxy-2,2,6-trimethylcyclohexanone. This work partly supported by the Sasakawa Scientific Research Grant from The Japan Science Society.

References

- 1 (a) T. Matsuno and M. Ookubo, Tetrahedron Lett., 1981, 4659; (b) T. Matsuno, M. Ookubo, T. Nishizawa and I. Shimizu, Chem. Pharm. Bull., 1984, 32, 4309.
- 2 A. Khare, G. P. Moss and B. C. L. Weedon, Tetrahedron Lett., 1973, 3921.

- 3 Y. Fujiwara, T. Maoka, M. Ookubo and T. Matsuno, Tetrahedron Lett., 1992, 33, 4941.
- 4 A. K. Chopra, A. Khare, G. P. Moss and B. C. L. Weedon, J. Chem. Soc., Perkin Trans. 1, 1988, 1383; B. C. L. Weedon, Pure Appl. Chem., 1973, 35, 113.
- 5 A. Rüttimann, Carotenoid Chemistry & Biochemistry, ed. G. Britton and T. W. Goodwin, Pergamon Press, Oxford, 1982, p. 71.
- 6 Y. Yamano and M. Ito, J. Chem. Soc., Perkin Trans. 1, 1993, 1599.
 7 H. Pauling, D. A. Andrews and N. C. Hindley, Helv. Chim. Acta, 1976, 59, 1233; Y. Yamano, C. Tode and M. Ito, J. Chem. Soc., P. 1005, Perkin Trans. 1, 1995, 1895.
- 8 L. Lopez, G. Mele, V. Fiandanese, C. Cardelliccho and A. Nacci, Tetrahedron, 1994, 50, 9097.
- 9 A. Rüttimann, G. Englert, H. Mayer, G. P. Moss and B. C. L. Weedon, Helv. Chim. Acta, 1983, 66, 1939.
- 10 S. Matsui, Bull. Chem. Soc. Jpn., 1984, 57, 426.

Paper 6/00099A Received 4th January 1996 Accepted 23rd April 1996